The estimated Net Worth of Dennis Slamon is at least $4.42 Milhão dollars as of 18 March 2024. Dennis Slamon owns over 10,000 units of Biomarin Pharmaceutical stock worth over $3,459,787 and over the last 11 years he sold BMRN stock worth over $500,999. In addition, he makes $454,270 as Independent Director at Biomarin Pharmaceutical.
Dennis has made over 2 trades of the Biomarin Pharmaceutical stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of BMRN stock worth $797,000 on 18 March 2024.
The largest trade he's ever made was exercising 10,000 units of Biomarin Pharmaceutical stock on 18 March 2024 worth over $797,000. On average, Dennis trades about 1,261 units every 58 days since 2014. As of 18 March 2024 he still owns at least 40,809 units of Biomarin Pharmaceutical stock.
You can see the complete history of Dennis Slamon stock trades at the bottom of the page.
Dr. Dennis J. Slamon, M.D., Ph.D., is an Independent Director of Biomarin Pharmaceutical Inc. Dr. Slamon joined our Board in March 2014. Dr. Slamon has served as Director of Clinical/Translational Research at UCLA’s Jonsson Comprehensive Cancer Center since June 1995 and has served as leader of the Revlon/UCLA Women’s Cancer Research Program at UCLA since its establishment in 1991. Since May 1996, Dr. Slamon has been a professor of medicine and Chief of the Division of Hematology/Oncology in the UCLA Department of Medicine and executive vice chair for research for UCLA’s Department of Medicine. He also serves as Director of the medical advisory board for the National Colorectal Cancer Research Alliance, a research and fund-raising organization that promotes advances in the treatment of colorectal cancer, and he is member of the board of Translational Research in Oncology, a global, non-profit, academic clinical research organization. A 1970 B.A. honors graduate in biology from Washington & Jefferson College and a 1975 graduate of the University of Chicago Pritzker School of Medicine, Dr. Slamon earned his Ph.D. in cell biology that same year. He completed his internship and residency at the University of Chicago Hospitals and Clinics, becoming chief resident in 1978. One year later, he became a fellow in the Division of Hematology/Oncology at UCLA where he currently serves on the faculty of medicine.
As the Independent Director of Biomarin Pharmaceutical, the total compensation of Dennis Slamon at Biomarin Pharmaceutical is $454,270. There are 16 executives at Biomarin Pharmaceutical getting paid more, with Jean-Jacques Bienaime having the highest compensation of $18,405,900.
Dennis Slamon is 70, he's been the Independent Director of Biomarin Pharmaceutical since 2014. There are 2 older and 20 younger executives at Biomarin Pharmaceutical. The oldest executive at Biomarin Pharmaceutical Inc. is Alan Lewis, 74, who is the Independent Director.
Dennis's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL, CA, 94901.
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy, eKathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: